Marvin Reineke

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

V. Beneš, T. Rausch, R. Bartenschlager, 2022, American Journal of Transplantation.

Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid

R. Bartenschlager, M. Zeier, P. Schnitzler, 2022, Frontiers in Medicine.

Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination

R. Bartenschlager, B. Tönshoff, M. Zeier, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose

R. Bartenschlager, M. Zeier, P. Schnitzler, 2023, Transplantation.

Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

R. Bartenschlager, M. Zeier, P. Schnitzler, 2022, Frontiers in Immunology.

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

R. Bartenschlager, M. Zeier, P. Schnitzler, 2022, Clinical Microbiology and Infection.

BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study

R. Bartenschlager, Hanns-Martin Lorenz, P. Schnitzler, 2023, Viruses.